Page 2 | Certara

Blog

Best Practices for pharma commercialization in market access

Learn best practices for your pharma commercialization strategy. See how to localize content in pharma…

CertaraMay 12, 2026

Press Coverage

PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

CertaraMay 12, 2026

Blog

4 Key Principles of Effective Pharmacokinetic Data Reporting

Improve pharmacokinetic data reports with clear structure, effective visuals, and strong data presentation for actionable…

CertaraMay 11, 2026

Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

CertaraMay 11, 2026

Press Release

Certara Reports First Quarter 2026 Financial Results

RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader…

CertaraMay 11, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle PillsburyMay 8, 2026

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

CertaraMay 8, 2026

Blog

Why CROs should use Pinnacle 21 Enterprise for late phase clinical data validation

How late phase CROs can improve sponsor submission readiness in Phase II and III trials…

CertaraMay 8, 2026

Blog

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

CertaraMay 8, 2026

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

CertaraMay 7, 2026

Best Practices for pharma commercialization in market access

PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials

4 Key Principles of Effective Pharmacokinetic Data Reporting

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Certara Reports First Quarter 2026 Financial Results

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Why CROs should use Pinnacle 21 Enterprise for late phase clinical data validation

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

Designing Drug Development Programs for Reimbursement Success

Newsletter sign up

Quick links

Solutions

Contact